How profitable is Travere Therapeutics Inc. (TVTX)?

In FY 2025 (10-K), TVTX converted $490.7M of revenue into a 97.9% gross margin, 0% operating margin, and $15.7M in free cash flow (3.2% FCF margin).

Stock Ratings / Health Care / TVTX / financials

DNTH (39) PTCT (63) ERAS (33) EWTX (41) ⌘ Pro Terminal →

Travere Therapeutics Inc. (TVTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$49.26 -2.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $48.97

Travere Therapeutics Inc. (TVTX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $4.75B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TVTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TVTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Travere Therapeutics Inc. (NASDAQ: TVTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $49.26 (-2.24% 1D, market cap $4.75B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, TVTX ranks #239 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TVTX compare to DNTH and PTCT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TVTX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -13.0%. By comparison, DNTH (Dianthus Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -30.7%, cap $4.61B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TVTX?

▼

Per TVTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001438533), Travere Therapeutics Inc. generated $490.7M in revenue (+110.5% YoY), -$25.5M in net income, and $15.7M in free cash flow against $605.2M in total assets and $220.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $48.97 (-0.59%)🧬 Disciplined Float (+0.52% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 3.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TVTX)Realized 20D OHLCV Swing Band: ±7.7%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY TVTX SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (27% of score)

Altman Z-Score 3.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 3.2% FCF Margin ($15.7M FCF) & 97.9% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (35.8) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$53.27-1.3% Next Q

Q2 (-2Q)

Grade C$52.58-3.3% Next Q

Q3 (-1Q)

Grade C$50.85-3.1% Next Q

Current

Grade D+$49.26-1.1% Hist 90D α

Trajectory: C (60) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TVTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TVTX currently carries a cautious 52/100 (D+) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($58.13) and Max Pain ($51.72) forces dealer call-delta covering toward $72.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TVTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TVTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TVTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$15.7M (3.2% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $145.2M

FY24

Rev $233.2M

FY25

Rev $490.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$490.7M	97.9%	-12.8%	-$25.5M	$15.7M	-20.5%
FY 2024	$233.2M	96.7%	-138.9%	-$321.5M	-$248.0M	-45%
FY 2023	$145.2M	92%	-267.2%	-$111.4M	-$286.6M	-19.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TVTX)

✓Walkthrough of TVTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TVTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.69%🛡️ HOLDING TREND SUPPORT

2026-11-03O $50.57H $50.57L $49.26C $49.26VOL 1.14M

RES: $72.37SUP: $48.86SMA50: $58.13SMA200: $46.95

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TVTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TVTX Butterfly Map → + Track TVTX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

11.2%/yr Implied 5Y Growth

vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TVTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TVTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TVTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TVTX)

Health Care Rank #239 of 1015 ⚔️ DNTH vs TVTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TVTX vs. DNTH, PTCT, ERAS, EWTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Travere Therapeutics Inc. (TVTX) ranks #239 by composite RQD confidence (52/100, grade D+) and #167 by equity capitalization ($4.75B). Within this direct 5-issuer industry benchmark cohort, PTCT leads on earnings valuation at 7.9x trailing P/E, while PTCT leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PTCT currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with TVTX at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TVTX ACTIVE Travere Therapeutics Inc.	D+	52/100	—	96.0%	-13.0%	-2.24%	$4.75B	Benchmark Subject
DNTH Dianthus Therapeutics Inc.	D-	39/100	—	—	-30.7%	-0.16%	$4.61B	/dnth-vs-tvtx →
PTCT PTC Therapeutics Inc.	C	63/100	7.9x	—	85.0%	+1.52%	$5.01B	/ptct-vs-tvtx →
ERAS Erasca Inc.	E	33/100	—	—	-35.0%	-2.09%	$5.02B	/eras-vs-tvtx →
EWTX Edgewise Therapeutics Inc.	D-	41/100	—	—	-31.9%	-2.03%	$4.22B	/ewtx-vs-tvtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001438533 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Travere Therapeutics Inc. (TVTX) reported GAAP revenue of $490.7M (+110.5% vs. FY2024 revenue of $233.2M , and +237.9% cumulative change since FY2023) , GAAP net income of -$25.5M, operating cash flow of $37.8M, and free cash flow of $15.7M (+106.3% YoY). On the balance sheet, TVTX closed FY2025 with $605.2M in total assets against $220.7M in total debt (Altman Z-Score: 3.44, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$490.7M	-$25.5M	$37.8M	$15.7M	$605.2M	$220.7M
FY2024 (FY)	2024-12-31	$233.2M	-$321.5M	-$237.5M	-$248.0M	$594.1M	$240.8M
FY2023 (FY)	2023-12-31	$145.2M	-$111.4M	-$280.0M	-$286.6M	$2.62B	$613.5M

3. TVTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TVTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TVTX compare to DNTH and PTCT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TVTX?

Where is TVTX trading relative to its 50-day, 200-day, and 52-week technical levels?

TVTX last traded at $49.26 (-2.24% on volume of 2,905,275 shares), positioning the stock -15.26% below its 50-day simple moving average ($58.13) and +4.92% above its 200-day simple moving average ($46.95). Across its 52-week range of $22.59 to $68.73, TVTX sits at the 57.8% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($45.47 to $53.05).

Direct Sub-Reports: TVTX RQD Cockpit TVTX 12M Forecast TVTX Earnings & Move TVTX Dividends & DRIP TVTX Insiders & 13F TVTX Whale Options TVTX Profit Sankey TVTX News & Why

ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ SEC XBRL & RQD VERIFIED

TVTX — Travere Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Travere Therapeutics Inc. (TVTX) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $49.26 (-2.24% 1D, market capitalization $4.75B).

Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of -13.0%, gross margin of 96.0%, operating margin of -12.8%, and free cash flow yield of 0.33%.
Whale 13F & Options Flow (8/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (14/20): Incorporates a 1.08x equity beta, Altman Z-Score of 3.44, Piotroski F-Score of 7/9, and Debt/Equity of 1.79x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Travere Therapeutics Inc. (TVTX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe specific products, customers, or revenue mechanics. Gross margin is reported at 96% which indicates high gross profitability on reported revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Travere Therapeutics Inc. (TVTX) reported $490.7M in annual revenue (up from $233.2M in FY2024, +110.5% YoY) and -$25.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($145.2M revenue, -$111.4M net income) through FY2025, TVTX scaled operating cash flow to $37.8M and free cash flow to $15.7M, backed by $605.2M in total assets against $220.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 52/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.33% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $22.59 – $68.73 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -12.8% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlations and 2nd-order bottlenecks cannot be mapped from the provided material. An investor should note that the absence of graph linkage is a data gap, not evidence of independence from suppliers or partners.

Key Question #1: Can TVTX sustain or expand its -12.8% operating margin and -13.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $490.7M and free cash flow of $15.7M, how will capital allocation balance growth reinvestment against $220.7M in total debt?
Key Question #3: How sensitive is TVTX's 18.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

TVTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Travere Therapeutics Inc. (TVTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TVTX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago

Travere Therapeutics, Inc. (TVTX) stock price, news, quote and history

Yahoo Finance Singapore report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Travere Therapeutics (TVTX) Is Down 6.7% After New FILSPARI Data And Patent Extension - What's Changed

Yahoo Finance report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Travere Therapeutics, Inc. Estimates – NASDAQ:TVTX

TradingView report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Travere Therapeutics (TVTX) Set to Report Q3 Earnings Amid Mixed Growth Signals

GuruFocus report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

10 Health Care Stocks Whale Activity In Today’s Session

Benzinga report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Corcept Therapeutics (CORT) and Incyte (INCY)

The Globe and Mail report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

The CEO exercises options at $8.93 and sells shares in Travere Therapeutics (TVTX).

Stock Titan report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

Travere Therapeutics Inc. Common Stock (TVTX) Stock Price Today: $50.39

Pluang report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TVTX Bull vs. Bear Conversation Board — What's Your Call at $49.26?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TVTX 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $65.51 (+30.0%)

📌 Pinned Debate

Revenue grew from $145.2M in FY 2023 to $490.7M in FY 2025 and FY 2025 FCF turned positive at $15.7M, with a 96% gross margin and a Pio

Here is why I am bullish on TVTX here at $50.39: Revenue grew from $145.2M in FY 2023 to $490.7M in FY 2025 and FY 2025 FCF turned positive at $15.7M, with a 96% gross margin and a Piotroski F-Score of 7/9.. Compare TVTX's -12.8% operating margin and -13.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $47.87 are getting bought.

EarningsSniper 🐂 BULL

@RedlineAuditor Shorting a 8/20 institutional whale-flow stock at $50.39 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $38.30 (-24.0%)

Spot @ $50.39

ROIC is -13%, operating margin is -12.8%, FCF yield is 0.33%, and Debt/Equity is 1.79, with the RQD composite at 52 (D+).

ROIC is -13%, operating margin is -12.8%, FCF yield is 0.33%, and Debt/Equity is 1.79, with the RQD composite at 52 (D+).. Look at the math on TVTX: paying 18.0x forward P/E for -13.0% ROIC and -12.8% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $44.34 before getting long.